High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4157-4164

  Anagnostou, Valsamo K ^a   Bepler, Gerold ^c   Syrigos, Konstantinos N ^b   Tanoue, Lynn ^a   Gettinger, Scott ^b   Homer, Robert J ^a   Boffa, Daniel ^a   Detterbeck, Frank ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; EARLY CANCER; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67449138837     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0099     Document Type: Article

References (45)

1. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTORpa thway. Curr Opin Cell Biol 2005;17:596-603.
2. Sabatini DM. mTORand cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734 (Pubitemid 44286004)
3. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-262
4. Thomas G, Hall MN. TOR signalling and control of cell growth. Current opinion in cell biology 1997;9:782-787 (Pubitemid 27517266)
5. Faivre S, Kroemer G, Raymond E. Current development of mTORi nhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688 (Pubitemid 44151605)
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945
7. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-1 adipocytes. The Journal of biological chemistry 2005;280:40406-40416 (Pubitemid 41780527)
8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101
9. Mahajan PB. Modulation of transcription of rRNA genes by rapamycin. International journal of immunopharmacology 1994;16:711-721 (Pubitemid 24271863)
10. Leicht M, Simm A, Bertsch G, Hoppe J. Okadaic acid induces cellular hypertrophy in AKR-2B fibroblasts: involvement of the p70S6 kinase in the onset of protein and rRNA synthesis. Cell Growth Differ 1996;7:1199-1209 (Pubitemid 26360700)
11. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49:415-421
12. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430 (Pubitemid 44050136)
13. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995;268:100-102
14. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-10319 (Pubitemid 32803017)
15. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited byAkt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-657 (Pubitemid 34993700)
16. Lee L, Sudentas P, Donohue B, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005;42:213-227 (Pubitemid 40171186)
17. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biologic Chem 1998;273:14424-14429 (Pubitemid 28319162)
18. Grewe M, Gansauge F, Schmid R M, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999;59:3581-3587 (Pubitemid 29381856)
19. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-573 (Pubitemid 2164735)
20. Aoki K, Ogawa T, Ito Y, Nakashima S. Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 2004;11:375-379
21. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-759 (Pubitemid 40568794)
22. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127 (Pubitemid 39485684)
23. Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor genemutation in lung cancer with natural resistance to gefitinib (IRESSA). Brit J Cancer 2005;92:1711-1719 (Pubitemid 40756483)
24. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-361 (Pubitemid 40980358)
25. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-5304 (Pubitemid 46206983)
26. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918 (Pubitemid 41103603)
27. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-5356 (Pubitemid 46206988)
28. Travis WD BE, Muller-Hermelink HK, Harris CC. WHO classification of tumors of the lung, pleura and mediastinum. Lyon: IARC Press; 2004.
29. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-15.
30. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327 (Pubitemid 35373567)
31. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259 (Pubitemid 39487712)
32. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537 (Pubitemid 40613318)
33. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12:5755-5763 (Pubitemid 44629606)
34. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-261 (Pubitemid 38114106)
35. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Brit J Cancer 2006;95:1148-1154 (Pubitemid 44660065)
36. Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitour Cancer 2007;5:379-385 (Pubitemid 47584475)
37. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13:758-63s. (Pubitemid 46220110)
38. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-4270
39. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005;11:4338-4340 (Pubitemid 40825621)
40. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059 (Pubitemid 39534841)
41. Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of nonsmall cell lung cancer. Clin Cancer Res 2004;10:293-300. (Pubitemid 38114192)
42. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826 (Pubitemid 32295062)
43. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. Drosophila S6 kinase: a regulator of cell size. Science1999;285:2126-2129
44. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487 (Pubitemid 34686329)
45. Neufeld TP, de la Cruz AF, Johnston LA, Edgar BA. Coordination of growth and cell division in the Drosophila wing. Cell 1998;93:1183-1193 (Pubitemid 28307423)